Company Overview and News


Add MNKD
to your dashboard

Headline News

MannKind: Afrezza Scripts Remain Flat As Holiday Season Approaches

21h seekingalpha
MannKind (MNKD) investors saw Afrezza scripts come in for the week of 11/10 slightly higher than the previous week, but essentially flat. This is a period where traction is needed if MannKind hopes to hit the re-stated low end of net revenue guidance of $6 million. Simply stated, the company needs sales to ramp up substantially in a time period where it is typically tough to demonstrate sales traction with prescription drugs. (67-0)

MannKind: Insider Trading, Short Interest, And Catalysts, Oh My

2017-11-16 seekingalpha
MannKind Corp. (MNKD) has had some nice volatility following its FDA label change, with things now settling down, as the stock has seemingly found a landing spot around $3 a share. Management has been bullish on the stock, as evidenced by insider trading over 2017, with another recent big purchase at a price near double the current share price. With a lot of shorts caught off guard with momentum following the positive FDA label change, the stock reached new recent highs that few could have predicted. (67-0)

Arena Q3: Loss But Progress On Pipeline

2017-11-15 seekingalpha
Last week Arena Pharmaceuticals (ARNA) reported its Q3 2017 earnings, and investors can clearly see why the company is a speculative play. Revenue from the Belviq franchise and the toll manufacturing are underwhelming when stacked up against operating costs, research and development costs, and the costs associated with settling a class action suit. That being said, the company has a robust pipeline and is advancing it in some key areas. (68-0)

MannKind - Afrezza Scripts And The Special Meeting

2017-11-10 seekingalpha
For MannKind to meet its guidance it needs $3 million in net revenue over next 8 weeks. (67-1)

Short Sellers Grow More Selective on Major Biotechs

2017-11-10 247wallst
The short interest data are out for the most recent settlement date, October 31. Generally speaking, companies within the biotech industry are considered to be a riskier group of stocks, with big potential upside and big potential downside. The health care sector in general has rallied since Donald Trump won the presidency, but now that the fate of the ACA is uncertain, the health care rally is called into question. (287-2)

MannKind's (MNKD) CEO Michael Castagna on Q3 2017 Results - Earnings Call Transcript

2017-11-08 seekingalpha
Welcome ladies and gentlemen and thank you for standing by. Welcome to the MannKind Corporation 2017 Third Quarter Conference Call. At this time all participants are in a listen-only mode. Later we will conduct a question-and-answer session. [Operator Instructions]. As a reminder this call is being recorded on November 07, 2017 and will be available for playback on MannKind's website shortly after the conclusion until November 21st. (67-1)

MannKind Corporation 2017 Q3 - Results - Earnings Call Slides

2017-11-07 seekingalpha
The following slide deck was published by MannKind Corporation in conjunction with their 2017 Q3 earnings call. (67-0)

MannKind Corporation to Host Earnings Call

2017-11-07 accesswire
(67-0)

MannKind Earnings On Tap - What We Know Going In

2017-11-07 seekingalpha
MannKind (MNKD) will be hosting its Q3 quarterly conference call today after the market closes. In many ways some of the anticipation is muted because the company gave some financial details when it did a direct offering of shares. We know the range for gross revenue as well as net revenue. We also know the amount of cash that the company finished Q3 with. These numbers leave little room for surprise in the call. (67-0)

MannKind Scripts Rebound - Why The Equity Is Volatile

2017-11-06 seekingalpha
Before giving the data update this week, I wanted to take a moment to cover some ground. (67-0)

MannKind - Afrezza Scripts Flat As Company Prepares For Q2 Conference Call

2017-10-30 seekingalpha
MannKind (MNKD) investors have seen a lot of action and volatility in the stock, but sales of Afrezza have now been pretty flat for 3 consecutive weeks. For the week ending October 20th Afrezza scripts came in at just above 400, putting a bit of a stall in sales traction. Meanwhile, MannKind has announced that it will be hosting its Q3 conference call on November 7, 2017. Much of the financial information related to Q3 has already been released, so the call will likely focus on what the company is planning on doing in 2018 rather than addressing what appears to be a guidance miss in the second half of 2017. (67-0)

Short Sellers Chase Biotechs Higher

2017-10-25 247wallst
The short interest data are out for the most recent settlement date, October 13. Generally speaking, companies within the biotech industry are considered to be a riskier group of stocks, with big potential upside and big potential downside. The health care sector in general has rallied since Donald Trump won the presidency, but now that the fate of the ACA is uncertain, the health care rally is called into question. (287-5)

MannKind: Bankruptcy Fears Fade Away

2017-10-24 seekingalpha
Key takeaway - MannKind's debt holders are betting on the company, so should high risk/reward investors. (67-1)

Biotech Analysis Central: Daily Pharma News - October 23, 2017

2017-10-24 seekingalpha
Welcome to Biotech Analysis Central Daily News, a daily news report and analysis about what has happened lately in the biotech industry. (375-1)

MannKind And Biomm SA Announce The Filing Of Afrezza In Brazil - While Debt Renegotiation Happens

2017-10-24 seekingalpha
Exchanged senior convertible notes of approximately $27.7 million due August 2018 for senior convertible notes in the amount of approximately $23.7 million due October 2021 and 973,236 shares. (68-0)

Stock Research Report

MannKind Corporation is a biopharmaceutical company focused on the discovery, development, and commercialization of therapeutic products for diseases such as diabetes. Its only approved product, Afrezza, is a rapid-acting inhaled insulin that was approved by the FDA on June 27, 2014 to improve glycemic control in adult patients with diabetes. Afrezza became available by prescription in United States retail pharmacies in February 2015. According to the Centers for Disease Control and Prevention, 30.3 million people in the United States had diabetes in 2015. Globally, the International Diabetes Federation has estimated that approximately 415.0 million people had diabetes in 2015 and approximately 642.0 million people will have diabetes by 2040.

Afrezza is a rapid-acting inhaled insulin used to control high blood sugar in adults with type 1 and type 2 diabetes. The product consists of a dry powder formulation of human insulin delivered from a small portable inhaler. Administered at the...

Click for full article
CUSIP: 56400P201